Reprogramming chemoimmunotherapy via biomimetic cell membrane- clay platform to amplify prime–boost antitumor immunity
Source abstract
Abstract
Chemoimmunotherapy has emerged as a promising strategy by combining chemotherapy with immunotherapy in cancer treatment. However, conventional chemoimmunotherapy strategies typically administer chemotherapy or immunogenic cell death (ICD)-induced chemotherapy prior to immunotherapy, which can compromise immune responsiveness due to toxicity, drug-induced immunosuppression and insufficient immune memory formation. As a result, therapeutic efficacy is critically influenced by the temporal order of immune activation and cytotoxic treatment. In this work, we reprogram the conventional chemoimmunotherapy sequence by developing an immune-priming-enabled chemoimmunotherapy strategy (immunotherapy prior to trimodal photochemotherapy) using cancer cell membrane-coated layered double hydroxide biomaterials (CCM-LDHs). BSA coated CpG-associated LDHs has been established as an immunomodulatory adjuvant to promote immune responses of CCM and reduce immune escape. By precisely modulating the CCM to LDHs ratio, the biomimetic CCM-LDHs can act as either antigen reservoirs to promote dendritic cell activation and T-cell priming or serve as a homologous tumor targeting to enhance the cellular uptake of drugs to promote their efficacy. In vitro and in vivo studies demonstrate immune priming followed by ICD-induced photochemotherapy provokes stronger cytotoxic T-cell responses and establishes robust immunological memory compared with the conventional ICD-induced chemoimmunotherapy, thereby supporting long-term anti-tumor immune surveillance.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Graphene and Nanomaterials Applications · Nanoplatforms for cancer theranostics · Therapeutic Uses of Natural Elements
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (52)
Show source-provided references
1. Tumor microenvironment‐activatable prodrug vesicles for nanoenabled cancer chemoimmunotherapy combining immunogenic cell death induction and CD47 blockade10.1002/adma.201805888 ↗
2. Prodrug‐based versatile nanomedicine for enhancing cancer immunotherapy by increasing immunogenic cell death10.1002/smll.202000214 ↗
3. Nanoscale coordination polymers induce immunogenic cell death by amplifying radiation therapy mediated oxidative stress
4. Tumor microenvironment responsive nanogel for the combinatorial antitumor effect of chemotherapy and immunotherapy10.1021/acs.nanolett.7b03186 ↗
5. A bio-responsive, cargo-catchable gel for postsurgical tumor treatment via ICD-based immunotherapy10.1016/j.jconrel.2022.04.015 ↗
6. Immunotherapy, immunogenic cell death by neoadjuvant oxaliplatin and radiation protects against metastatic failure in high-risk rectal cancer10.1007/s00262-019-02458-x ↗
7. Phototherapy and anti-GITR antibody-based therapy synergistically reinvigorate immunogenic cell death and reject established cancers10.1016/j.biomaterials.2020.120648 ↗
8. A new sono-chemo sensitizer overcoming tumor hypoxia for Augmented Sono/Chemo-Dynamic therapy and robust immune-activating response
9. Impact of (chemo) radiotherapy on immune cell composition and function in cervical cancer patients10.1080/2162402X.2016.1267095 ↗
10. Carrier-free nanoassembly of doxorubicin prodrug and siRNA for combinationally inducing immunogenic cell death and reversing immunosuppression10.1016/j.nantod.2020.100924 ↗
11. Medium dose intermittent cyclophosphamide induces immunogenic cell death and cancer cell autonomous type I interferon production in glioma models10.1016/j.canlet.2019.11.025 ↗
12. Nanoparticle-mediated synergistic chemoimmunotherapy for tailoring cancer therapy: recent advances and perspectives10.1186/s12951-021-00861-0 ↗
13. T-Cell-Mimicking nanoparticles for cancer immunotherapy10.1002/adma.202003368 ↗
14. Harnessing innate immunity using biomaterials for cancer immunotherapy10.1002/adma.202007576 ↗
15. Biomaterials to enhance antigen-specific T cell expansion for cancer immunotherapy10.1016/j.biomaterials.2020.120584 ↗
16. Biomaterials tools to modulate the tumour microenvironment in immunotherapy10.1038/s44222-022-00004-6 ↗
17. Treating metastatic cancer with nanotechnology10.1038/nrc3180 ↗
18. Using immunotherapy to boost the abscopal effect10.1038/nrc.2018.6 ↗
19. A DNA nanodevice-based vaccine for cancer immunotherapy10.1038/s41563-020-0793-6 ↗
20. Surgical tumor-derived personalized photothermal vaccine formulation for cancer immunotherapy10.1021/acsnano.8b07371 ↗
21. Modularly programmable nanoparticle vaccine based on polyethyleneimine for personalized cancer immunotherapy10.1002/advs.202002577 ↗
22. Supramolecular assembled programmable nanomedicine as in situ cancer vaccine for cancer immunotherapy
23. Coordination and Redox dual‐responsive mesoporous organosilica nanoparticles amplify immunogenic cell death for cancer chemoimmunotherapy
24. Combined local immunostimulatory radioisotope therapy and systemic immune checkpoint blockade imparts potent antitumour responses10.1038/s41551-018-0262-6 ↗
25. Nanoparticle‐enhanced. radiotherapy to trigger robust cancer immunotherapy
26. Enhancing cancer chemo-immunotherapy: innovative approaches for overcoming immunosuppression by functional nanomaterials
27. Biomimetic diselenide‐bridged mesoporous organosilica nanoparticles as an x‐ray‐responsive biodegradable carrier for chemo‐immunotherapy
28. Cancer-cell-membrane-coated nanoparticles with a yolk–shell structure augment cancer chemotherapy10.1021/acs.nanolett.9b03817 ↗
29. Cancer cell membrane‐coated nanoparticles for personalized therapy in patient‐derived xenograft models10.1002/adfm.201905671 ↗
30. Cancer cell membrane camouflaged Semi‐Yolk@ spiky‐shell nanomotor for enhanced cell adhesion and synergistic therapy
31. Personalized nanovaccine coated with Calcinetin-Expressed cancer cell membrane antigen for cancer immunotherapy10.1021/acs.nanolett.1c03004 ↗
32. Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery10.1021/nl500618u ↗
33. Recent advances in cancer cell membrane-based nanoparticles and cancer cell-derived small extracellular vesicles as drug delivery platforms10.1002/anbr.202500008 ↗
34. Biomimetic 2D layered double hydroxide nanocomposites for hyperthermia-facilitated homologous targeting cancer photo-chemotherapy10.1186/s12951-021-01096-9 ↗
35. Recent advances in cell‐mediated drug delivery systems for nanomedicine and imaging
36. A peritumorally injected immunomodulating adjuvant elicits robust and safe metalloimmunotherapy against solid tumors
37. Efficient immunotherapy of drug-free layered double hydroxide nanoparticles via neutralizing excess acid and blocking tumor cell autophagy10.1021/acsnano.2c02183 ↗
38. Nanovaccine's rapid induction of anti-tumor immunity significantly improves malignant cancer immunotherapy10.1016/j.nantod.2020.100923 ↗
39. “Trojan horse” nanoparticle-delivered cancer cell membrane vaccines to enhance cancer immunotherapy by overcoming immune-escape10.1039/D2BM01432G ↗
40. Phototherapy and anti-GITR antibody-based therapy synergistically reinvigorate immunogenic cell death and reject established cancers10.1016/j.biomaterials.2020.120648 ↗
41. Multifunctional nano‐biomaterials for cancer therapy via inducing enhanced immunogenic cell death10.1002/smtd.202201457 ↗
42. Efficient immunotherapy of drug-free layered double hydroxide nanoparticles via neutralizing excess acid and blocking tumor cell autophagy10.1021/acsnano.2c02183 ↗
43. Pre-coating layered double hydroxide nanoparticles with albumin to improve colloidal stability and cellular uptake10.1039/C5TB00248F ↗
44. Co-delivery of siRNAs and anti-cancer drugs using layered double hydroxide nanoparticles10.1016/j.biomaterials.2013.12.095 ↗
45. Immunogenic cell death in anticancer chemotherapy and its impact on clinical studies10.1016/j.canlet.2018.08.028 ↗
46. A general strategy towards personalized nanovaccines based on fluoropolymers for post-surgical cancer immunotherapy10.1038/s41565-020-00781-4 ↗
47. Engineering dendritic cell vaccines to improve cancer immunotherapy10.1038/s41467-019-13368-y ↗
48. Molecular and nanoengineering approaches towards activatable cancer immunotherapy10.1039/C9CS00773C ↗
49. Nanoparticle-enhanced chemo-immunotherapy to trigger robust antitumor immunity10.1126/sciadv.abc3646 ↗
50. Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma10.1016/j.ctrv.2014.06.012 ↗
51. Injectable, spontaneously assembling, inorganic scaffolds modulate immune cells in vivo and increase vaccine efficacy10.1038/nbt.3071 ↗
52. Infection-mimicking materials to program dendritic cells in situ10.1038/nmat2357 ↗